Cases That Test Your Skills

Can a wakefulness-promoting agent augment schizophrenia treatment?

Current Psychiatry. 2002 July;1(7):52-57

References

1. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.

2. Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-46.

3. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-8.

4. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.

5. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60(6):358-63.

6. Beasley CM, Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125-37.

7. Blackburn GL. Weight gain and antipsychotic medication. J Clin Psychiatry 2000;61(suppl 8):36-41.

8. Gawin FH, Khalsa ME, Ellinwood E. Stimulants. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. Washington, DC: American Psychiatric Press, 1994.

9. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996;126(4):286-92.

10. Warot D, Coruble E, Payan C, et al. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo. Eur Psychiatry 1993;8:201-8.

11. Duteil J, Rambert FA, Pessonnier J, et al. Central alpha1-adrenergic stimulation in relation to the behaviour stimulating effects of modafinil: studies with experimental animals. Eur J Pharmacol 1990;180:49-58.

12. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999;39:30-40.

13. Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999;35(suppl):S51-S60.

14. Beasley CM, Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol 1996;124(1-2):159-67.

15. Marder SR. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996;57(suppl 11):26-30.

16. Physician’s Desk Reference (55th ed). Montvale, NJ: Medical Economics, 2001.

17. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61(5):378-81.

18. Maguire GA. CNS News. Supplement August 2001;6-10.